Skip to main content

Search

Show all results for

Home

Person

Veronica Setola

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2026 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (3)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord

Patrick Aebischer, Bernard Schneider, Christopher Towne, Veronica Setola, Elisabeth Anne Dirren

In the context of motoneuron diseases, gene delivery as an experimental or therapeutic approach is hindered by the challenge to specifically target cell populations that are widely distributed along the spinal cord. Further complicating the task, transgene ...

Mary Ann Liebert2014

Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool

Patrick Aebischer, Nicolas Bouche, Jean-Charles Bensadoun, Maria del Carmen Sandi Perez, Rolf Gruetter, Maria Isabel Cordero Campana, Osiris Marroquin Belaunzaran, Veronica Setola, Maurizio Molinari

BACKGROUND: Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current pri ...

Public Library of Science2011

Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice

Patrick Aebischer, Bernard Schneider, Christopher Towne, Veronica Setola

A major challenge in neurological gene therapy is delivery of the transgene to sufficient cell numbers in an atraumatic manner. This is particularly difficult for motor neuron (MN) diseases that have cells located across the entire spinal cord, brain stem, ...

Elsevier2010